Vikram Jagannathan
About Vikram Jagannathan
Vikram Jagannathan serves as the Director of Drug Safety at Nektar Therapeutics, a position he has held since 2020. He has extensive experience in drug safety, regulatory assessment, and adverse event reporting across various therapeutic areas.
Current Role at Nektar Therapeutics
Vikram Jagannathan serves as the Director of Drug Safety at Nektar Therapeutics, a position he has held since 2020. In this role, he oversees drug safety operations, ensuring compliance with regulatory requirements and the safety of therapeutic products. His responsibilities include managing safety databases and conducting aggregate data reviews. His expertise in MedDra coding enhances the accuracy and efficiency of safety assessments.
Previous Experience at Sanofi-Aventis
Prior to his current role, Vikram Jagannathan worked at Sanofi-Aventis. He began as an Early Regulatory Assessor for a brief period in 2008, followed by a three-year tenure as a Medical Evaluator from 2008 to 2011 in Bridgewater, New Jersey. During his time at Sanofi-Aventis, he gained valuable experience in drug safety and regulatory processes.
Education and Medical Qualifications
Vikram Jagannathan earned his Bachelor of Medicine, Bachelor of Surgery (MBBS) from Sri Ramachandra Medical College and Research Institute. This foundational medical education provided him with a strong background in clinical medicine, which supports his current work in drug safety and regulatory affairs.
Expertise in Drug Safety and Therapeutic Areas
Vikram Jagannathan possesses extensive expertise in drug safety, particularly in MedDra coding and aggregate data review and writing. His diverse therapeutic area experience includes Oncology, Hematology, and Infectious Diseases, among others. He has significant experience in adverse event reporting in both clinical trials and post-marketing settings, as well as in Ex-US/final rule assessments.